<div id="readability-page-1"><div><p><span>Sarepta Therapeutics Inc </span><span>:</span></p><ul><li>SAREPTA THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION FOR SRP-1005, ITS INVESTIGATIONAL TREATMENT FOR HUNTINGTON’S DISEASE</li><li>SAREPTA THERAPEUTICS INC - FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026</li><li>SAREPTA THERAPEUTICS INC: FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026</li></ul></div></div>

<p>Sarepta Therapeutics Inc :SAREPTA THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION FOR SRP-1005, ITS INVESTIGATIONAL TREATMENT FOR HUNTINGTON’S DISEASESAREPTA THERAPEUTICS INC - FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026SAREPTA THERAPEUTICS INC: FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026</p>

Reuters

Proshares Ultra Nasdaq Biotech

VG Health

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Sarepta Therap

Tradr 2X Long SRPT Daily ETF

Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease